Please login to the form below

Not currently logged in
Email:
Password:

EMA/FDA to continue collaboration

The US Food and Drug Administration and the European Medicines Agency are to continue to improve efforts to work together more closely following two successful pilots

The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are to continue to improve efforts to work together more closely following two successful pilots.

The two regulatory bodies, which cover the US and the EU regions respectively, said the joint good clinical practice (GCP) inspection pilot programme achieved its aims to increase information-sharing and collaboration on inspections relating to clinical trials.

The agencies shared 250 documents relating to 54 different medicines and organised 13 collaborative inspections of clinical trials. The EMA said these efforts help ensure data submitted for drug approvals is of an appropriate standard.

Increased collaboration is part of the FDA's strategy to ensure the safety and quality of imported products in response to challenges posed by rapidly rising imports of FDA-regulated products and an increasingly complex global supply chain.

The plans were described in the Pathway to Global Product Safety and Quality report, with calls for the agency to transform the way it conducts business and build upon relationships with regulatory partners around the world.

Deborah M Autor, FDA deputy commissioner for global regulatory operations and policy, said: "It is imperative that FDA work closely with its counterparts in order to ensure the safety and quality of products and the integrity of clinical trials. We cannot do it alone."

Australia's Therapeutic Goods Administration has also teamed up with the EMA and FDA on a joint active pharmaceutical ingredients (API) inspections pilot programme.

The programme was to improve information-sharing and collaboration on API inspections among the participating authorities.

Participants shared their surveillance lists and found 97 sites common to all three regions, resulting in the exchange of nearly 100 inspection reports and nine joint inspections. Based on the results of the two pilots, the EMA and the FDA have agreed to continue with their collaboration on inspections.

3rd August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CMR

Specialising in medical device market research, our approach is people-centric and we thrive on making connections with clients and research...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics